CA-XENCO-MEDICAL
On January 11th, trailblazing medical technology company Xenco Medical unveiled its convergent technology bridging Digital Health and Biomaterials by showcasing its TrabeculeX Continuum™ at the 2024 Consumer Electronics Show in Las Vegas, Nevada. Comprising the FDA-cleared TrabeculeX Bioactive Matrix™ and the TrabeculeX Recovery App™, the TrabeculeX Continuum is the first technology-enabled bridge between orthobiologics and digital health, unifying a patient’s biomaterial implantation and postoperative journey. Empowering surgeons who have implanted Xenco Medical’s FDA-cleared TrabeculeX Bioactive Matrix to enroll patients in the TrabeculeX Recovery App and engage in both Remote Therapeutic Monitoring and asynchronous video and text messaging, the TrabeculeX Continuum is an unprecedented intersection of regenerative medicine and digital health
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116950427/en/
On January 11th, trailblazing medical technology company Xenco Medical unveiled its convergent technology bridging Digital Health and Biomaterials by showcasing its TrabeculeX Continuum™ at the 2024 Consumer Electronics Show in Las Vegas, Nevada. Comprising the TrabeculeX Bioactive Matrix™ and the TrabeculeX Recovery App™, the TrabeculeX Continuum is the first technology-enabled bridge between orthobiologics and digital health, unifying a patient’s biomaterial implantation and postoperative journey. (Graphic: Business Wire)
Engineered to harness the hydroxycarbonate apatite-forming capabilities of bioglass in every TrabeculeX Bioactive Matrix, the regenerative biomaterial included in the TrabeculeX Continuum has been intricately designed by Xenco Medical to conduct three-dimensional bone-formation. Leveraging a complex surface topography, the TrabeculeX Bioactive Matrix’s novel architecture begins at the sub-micron scale and spans to the entire lattice itself. Bridging the journey from biomaterial implantation to full physical rehabilitation, the TrabeculeX Recovery App enables surgeons who’ve used a TrabeculeX Bioactive Matrix strip in their patient to prescribe and remotely monitor patient-specific physical rehabilitation plans with the ability to engage in asynchronous video and text messaging.
“As a surgical technology company devoted not only to our patients' intraoperative care but to their longitudinal recovery, we’ve committed ourselves to dissolving the barriers that currently exist in the siloed path from surgery to rehabilitation. With the TrabeculeX Continuum, we’re excited to introduce a connective technology that recognizes the full arc of a patient’s journey rather than a single instance of care,” said Xenco Medical Founder and CEO Jason Haider.
A pioneer in its application of advanced materials science to surgical instrument and implant design as well, Xenco Medical’s novel, materials science-driven portfolio of disposable composite polymer surgery systems and biomimetic titanium foam spinal implants have been adopted by healthcare facilities nationwide. In recognition of its groundbreaking technologies, Xenco Medical was named one of the World’s Most Innovative Companies by Fast Company Magazine in its esteemed 2023 list.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116950427/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom